Attached files
| file | filename |
|---|---|
| EX-99.1 - PROLOR Biotech, Inc. | v211624_ex99-1.htm |
|
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): February 16,
2011
PROLOR
BIOTECH, INC.
(Exact
Name of Registrant as Specified in Its Charter)
|
Nevada
|
000-52691
|
20-0854033
|
|
(State
or Other Jurisdiction of Incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
3
Sapir Street
Weizmann
Science Park
Nes-Ziona,
Israel 74140
|
|
(Address
of Principal Executive Office)
|
Registrant’s
telephone number, including area code (866)
644-7811
(Former
Name or Former Address, if Changed Since Last Report)
|
|
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
7.01. Regulation FD
Disclosure.
On
February 16, 2011, at 10:15 am ET, PROLOR Biotech, Inc., a Nevada corporation
(the “Company”), is
presenting certain slides (the “Presentation”) at the
Leerink Swann Hot Topics in Therapeutics: Roundtable Conference in
New York City. A copy of the Presentation is furnished as Exhibit
99.1 to this Current Report on Form 8-K and incorporated by reference in this
Item 7.01.
The
information contained in Item 7.01 of this Current Report on Form 8-K and
Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing by the Company under the Securities Act of 1933, as
amended.
ITEM
9.01. Financial Statements
and Exhibits.
(d) Exhibits.
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Slide
Presentation
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| PROLOR BIOTECH, INC. | |||
|
Date: February
16, 2011Date
|
By:
|
/s/ Shai Novik | |
| Shai Novik | |||
| President | |||
EXHIBIT
INDEX
|
Exhibit
Number
|
Description
|
|
|
99.1
|
Slide
Presentation
|